(0.17%) 5 140.25 points
(0.12%) 38 489 points
(0.23%) 17 888 points
(-0.26%) $83.63
(0.99%) $1.942
(0.34%) $2 355.10
(0.62%) $27.71
(1.66%) $937.40
(-0.15%) $0.933
(-0.31%) $10.99
(-0.28%) $0.798
(1.25%) $93.02
@ $0.850
发出时间: 13 Feb 2024 @ 04:20
回报率: -2.56%
上一信号: Feb 12 - 23:52
上一信号:
回报率: -3.19 %
Live Chart Being Loaded With Signals
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis...
Stats | |
---|---|
今日成交量 | 670 762 |
平均成交量 | 956 590 |
市值 | 78.78M |
EPS | $0 ( 2024-03-11 ) |
下一个收益日期 | ( $-0.0100 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.180 |
ATR14 | $0.00300 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Kirk Sigurd | Sell | 118 702 | Stock Option (right to buy) |
2024-03-14 | Tyree James L | Sell | 10 251 | Common Stock |
2024-02-21 | Schlessinger Sam | Buy | 17 151 | Common Stock |
2024-02-21 | Schlessinger Sam | Sell | 8 506 | Common Stock |
2024-02-21 | Schlessinger Sam | Sell | 17 151 | Restricted Stock Units |
INSIDER POWER |
---|
22.78 |
Last 98 transactions |
Buy: 4 490 251 | Sell: 3 194 471 |
音量 相关性
Assertio Holdings Inc 相关性 - 货币/商品
Assertio Holdings Inc 财务报表
Annual | 2023 |
营收: | $152.07M |
毛利润: | $96.82M (63.67 %) |
EPS: | $-4.67 |
FY | 2023 |
营收: | $152.07M |
毛利润: | $96.82M (63.67 %) |
EPS: | $-4.67 |
FY | 2022 |
营收: | $156.23M |
毛利润: | $137.49M (88.00 %) |
EPS: | $2.33 |
FY | 2021 |
营收: | $111.01M |
毛利润: | $95.18M (85.74 %) |
EPS: | $-0.0300 |
Financial Reports:
No articles found.
Assertio Holdings Inc
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。